eIF Inhibitors
Eukaryotic initiation factors (eIFs) are critical components of the protein synthesis machinery, specifically regulating the rate-limiting step of translation initiation. The eIF4F complex, consisting of the cap-binding protein eIF4E, the RNA helicase eIF4A, and the scaffold protein eIF4G, is a central node in this process. This complex integrates signals from the PI3K/Akt/mTOR and Ras/MAPK pathways to promote the translation of mRNAs containing long, structured 5'-untranslated regions (UTRs), which often encode oncogenic proteins such as c-Myc, cyclin D1, and VEGF. Overexpression or hyperactivation of eIF components, particularly eIF4E, is a hallmark of many human cancers and is associated with poor prognosis, tumor metastasis, and resistance to conventional therapies. Consequently, targeting the eIF4F complex has emerged as a robust strategy for anti-cancer drug development, aiming to selectively inhibit the translation of pro-survival and pro-growth proteins while sparing global protein synthesis.
Inhibitors of eIFs can be broadly classified based on their target within the initiation complex. eIF4E inhibitors include antisense oligonucleotides (ASOs) that reduce eIF4E mRNA levels, and small molecules that disrupt the eIF4E-eIF4G interaction or prevent eIF4E from binding to the 5' cap. eIF4A inhibitors, such as the rocaglates (e.g., silvestrol and its synthetic derivative zotatifin), act by clamping eIF4A onto RNA, thereby depleting the available pool of the helicase and blocking translation. Zotatifin is currently being evaluated in Phase I/II clinical trials for solid tumors. Another approach involves targeting the MNK1/2 kinases, which phosphorylate eIF4E; inhibitors like tomivosertib aim to reduce the oncogenic potential of eIF4E without completely blocking its basal activity.
Despite the promise, the development of eIF inhibitors faces challenges, including the potential for systemic toxicity due to the fundamental role of translation in normal cell physiology and the emergence of compensatory mechanisms. Beyond oncology, eIF inhibitors are being investigated for their antiviral properties, as many viruses rely on the host's eIF4F complex for the translation of viral genomes. For example, eIF4A inhibitors have shown potent activity against various RNA viruses, including coronaviruses and Zika virus. In the context of cancer therapy, combination strategies are particularly attractive. eIF inhibitors can sensitize tumors to BRAF or MEK inhibitors by preventing the translational rewiring that often leads to acquired resistance.
Furthermore, emerging evidence suggests that modulating translation can enhance the efficacy of immunotherapies by altering the tumor secretome and improving antigen presentation. Future research is focused on improving the selectivity and bioavailability of these compounds, with a particular emphasis on identifying biomarkers that can predict patient response to translation-targeted therapies.
